Krystal Biotech (KRYS) EBITDA Margin (2023 - 2026)
Krystal Biotech recorded quarterly EBITDA Margin of 45.7% in Q1 2026, down 4.85% quarter-over-quarter from 48.03% in Q4 2025, and up 452.0% year-over-year from 8.28% in Q1 2025.
Krystal Biotech's EBITDA Margin history runs 4 years deep, the most recent figure standing at 45.7% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 452.0% year-over-year to 45.7%; the TTM figure through Mar 2026 stood at 53.45% (up 1607.0% YoY), while the FY2025 annual figure was 52.98%, up 2258.0% from the prior year.
- EBITDA Margin came in at 45.7% for Q1 2026 at Krystal Biotech, down from 48.03% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 942.04% in Q3 2023 to a low of 0.01% in Q1 2024.
- A 4-year average of 120.59% and a median of 41.18% in 2025 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin tumbled 90706 bps in 2024 and surged 4611 bps in 2025, its largest moves.
- Krystal Biotech's EBITDA Margin stood at 23.05% in 2023, then soared by 108 bps to 48.05% in 2024, then slipped by 0 bps to 48.03% in 2025, then fell by 5 bps to 45.7% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 45.7%, 48.03%, and 81.09% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.24% |
| 10 | Krystal Biotech | 9.05 Bn | 8.23 Bn | 110.03 Mn | 45.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.70% |
| Dec 31, 2025 | 48.03% |
| Sep 30, 2025 | 81.09% |
| Jun 30, 2025 | 40.73% |
| Mar 31, 2025 | 41.18% |
| Dec 31, 2024 | 48.05% |
| Sep 30, 2024 | 34.98% |
| Jun 30, 2024 | 21.67% |
| Mar 31, 2024 | -0.01% |
| Dec 31, 2023 | 23.05% |
| Sep 30, 2023 | 942.04% |